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Simian virus 40 (SV40) vectors are efficient vehicles for gene delivery to hematopoietic and hepatic cells. To ensure their
replication incompetence and because of safety considerations, it is critical that the vectors do not contain T-antigen
sequences. Available packaging cell lines for T-antigen replacement vectors, COS and CMT4, contain considerable sequence
identity with the vectors, leading to homologous recombination and reacquisition of the T-antigen gene. We constructed a
packaging cell line, COT18, with minimal sequence identity to the vector. Vector stocks produced by passaging on COT18 had
high transducing activity and undetectable levels of T-antigen-positive, replication-competent contaminants. This cell linestocks
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Introduction. Simian virus 40 (SV40) is a promising
viral vector for efficient gene transfer into a variety of
human tissues, including the bone marrow (1–3) and the
liver (4, 5), both critical target organs for the treatment of
many diseases. The large SV40 T-antigen activates both
viral DNA replication and transcription of the viral late
genes. Hence, in T-antigen replacement vectors, deletion
of T-antigen ensures the production of replication-incom-
petent vectors that are also incapable of late gene ex-
pression. Thus, the inherent immunogenicity of both the
T-antigen protein and the structural late proteins is elim-
inated. These vectors are propagated in cell lines such
as COS (6), which are permissive for lytic growth of SV40
and supply the T-antigen in trans. However, passaging of
T-antigen mutants in COS cells results in the appearance
of recombinant wild-type virus (at a low frequency) as a
result of recombination with the endogenous SV40 ge-
nomes (6). Over the years, a number of investigators
have studied the emergence of such recombinants, usu-
ally detected as plaque-forming units (PFU) on CV-1 cells
(which do not contain T-antigen). The generation of re-
combinants is erratic and may reach a ratio of more than
1 PFU to 1000 T-antigen-deleted plasmids in three pas-
sages in COS-1 cells (7). Homologous recombination at
a high frequency was demonstrated between introduced
1 To whom correspondence and reprint requests should be
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vectors and endogenous SV40 in COS-1 cells and at an
even higher frequency in COS-7 cells (8). It was further
shown that recombination starts occurring early in the
life cycle (9). Detailed studies (10) revealed that reacqui-
sition of the T-antigen gene most probably occurs by two
homologous recombination events at sites of sequence
identity flanking the T-antigen gene. In the present study
we have constructed packaging cell lines that contain
minimal sequence identity with the vector. Indeed, the
generation of T-antigen-positive revertants was elimi-
nated. One of the cell lines, COT18, allows propagation of
high-titer stocks with minimal loss of transducing activity.
Results. Isolation of cell lines that carry a T-antigen
expression cassette with minimal sequence homology to
SV40 vectors. We constructed a T-antigen expression
cassette (plasmid pUMTB, Fig. 1A), in which T-antigen
transcription is driven by the mouse metallothionein pro-
moter and utilizes the bovine growth hormone polyade-
nylation signal. This strategy limits the identity between
the packaging cell line and the vector sequences from
over 2 kb (as in COS and CMT4 cells) to only 83 bp at the
3 end of the T-antigen coding sequence (Fig. 1B). This is
below the stretch of identity required for efficient homol-
ogous recombination in mammalian cells, which is esti-
mated to be between 200 and 300 bp (11).
CV-1 and Vero cells were used to construct cell lines
as described under Materials and Methods. Five of the
CV-1 clones and three of the Vero clones expressed. © 2002 Elsevier Science (USA)
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package SV40 vectors. The results showed that the Vero
derivatives were poor in vector production. Three of the
CV-1 derivatives, COT2, COT4, and COT18, were effective
in packaging SV40 vectors and were selected for further
studies.
Transducing Activity Is Lost after Repeated Passaging.
Initial studies with these packaging cell lines using a
number of vectors carrying glucocerebrosidase, LNGFR,
and lmrA suggested some irreproducibility in the prepa-
ration of stocks titered for infectious units (IU) as infec-
tive centers on CMT4 monolayers. Moreover, we noted
that stocks with a titer of 106 to 107 IU/ml and even higher
sometimes gave poor results when transgene expres-
sion was measured. To further investigate this issue,
experiments were conducted with the SV/luc vector,
which harbors the luc reporter gene. COT2, COT4,
COT18, and COS-1 were tested for vector production.
The IU titer of SV/luc vector preparations increased with
additional passages, reaching 106–107 IU/ml in the fifth
passage in all cell lines assayed (a typical experiment is
shown in Fig. 2A). Transducing activities were measured
by luminometry of infected COS-1 cells. The results of
repeated experiments showed that transducing activities
did not always correlate with IU titers (Figs. 2A and 2B):
We consistently observed that the luc-transducing activ-
ity of vectors prepared in the COS-1 and COT18 cell lines
first increased (for three to five passages) and then
started to decrease. In COT2 and COT4, luc-transducing
activity logarithmically decreased with every passage.
Transducing activity was consistently lost more rapidly in
COT2 and COT4 than in COT18 and COS-1. The discrep-
ancy between IU and transducing activities provides a
measure for the magnitude of defective vector accumu-
lation in a given stock.
To obtain additional evidence of the cell-specific na-
ture of this process, we performed the following experi-
ment. A second-passage SV/luc stock prepared in COT2
cells was divided and further passaged in parallel in both
COT2 and COS-1 cells. Remarkably, the luc-transducing
activity of the vector preparations that were transferred
from COT2 to COS-1 cells started to increase, while the
vector that continued to be passaged on COT2 cells
continued to accumulate defective vectors (Fig. 2C).
Transfection and passaging exclusively in COS-1 cells, in
a parallel experiment, showed a continuous increase in
luc-transducing activity.
FIG. 1. Plasmid maps. (A) Plasmid pUMTB contains a pUC bacterial
sequence backbone; approximately 650 bp of the mouse metallothio-
nein promoter up to the KpnI site (GenBank Accession No. X15128), the
T-antigen coding sequence nt 5179–2687 (GenBank Accession No.
J02400), and the bovine growth hormone polyadenylation fragment,
derived from plasmid pcDNA3 (Invitrogen) coordinates 984–1243. (B)
Physical map of the SV40 polyadenylation region. The vectors contain
the late SV40 genes including the region between the BamHI site
(coordinate 2533) and the BclI site (coordinate 2770). The pUMTB
construct carries a short (83-bp) overlap with the SV40 vectors, coor-
dinates 2687–2770. (C) Plasmid pSLB-luc contains the SV/luc vector
DNA inserted as a BamHI fragment into pBR332. T-antigen (coordinates
5171–2770) is replaced by the luc gene fragment (HindIII to XbaI)
derived from pGL3-basic (GenBank Accession No. U47295, coordi-
nates 53 to 1742).
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Vectors Acquire Deletions during Repeated Passaging.
Our previous studies (12) showed that plasmids that
contain the SV40 ori tend to accumulate deletions during
propagation in COS-1 cells. Smaller plasmids presum-
ably have a selective advantage in DNA replication
and/or packaging over large plasmids. Loss of transduc-
ing activity may result from the deletion of critical se-
quences in the expression cassette. To test for this
possibility we analyzed SV/luc vectors propagated in
COT2. Low-MW DNA was extracted from cells infected
with a fifth-passage SV/luc stock and analyzed by aga-
rose gel electrophoresis. The size of extracted DNA was
compared to the input vector following digestion with
restriction endonucleases, since the original plasmid
contained additional sequences for propagation in bac-
teria. The input vector digested with BamHI yielded two
fragments, the pBR322 fragment (4361 bp) and the ex-
cised SV/luc fragment (4561 bp), which comigrated as a
single band (Fig. 3A, lane 1). SV/luc vector DNA extracted
from infected COT2 cells and linearized with EcoRI was
expected to yield a single band. However, it produced
two bands, both of lower MW than the input vector (Fig.
3A, lane 3), demonstrating the formation of deletions
during passaging. Uncut low-MW DNA (Fig. 3A, lane 2)
was heterogeneous in size. All the bands hybridized with
a pSLB-luc probe (Fig. 3B). Similar results were obtained
with an SV40-based vector carrying the green fluores-
cent protein (GFP) reporter gene propagated for three
passages on COT2 cells (data not shown).
Plaque-Forming SV40 Is Not Produced in Vectors Pas-
saged on COT Cells. A major concern for gene therapy is
the emergence of replication-competent, T-antigen-bear-
ing viral particles that may propagate in the host. We next
inquired whether the recombination events described
above could lead to reacquisition by the vector of the
T-antigen sequences present in the packaging cells by
screening high-passage (fifth) SV/luc vector stocks pre-
pared on COS-1 and the COT cell lines for replication-
competent recombinants. The vector was passaged in
the respective cell lines, starting from the initial transfec-
tion, in parallel with mock-transfected control cultures.
FIG. 3. DNA analysis of vector passaged in COT2 cells. (A) COT2
cells were infected with the fifth-passage SV/luc vector stock, and
low-MW DNA was extracted 3 days postinfection, linearized with EcoRI,
and electrophoresed in parallel to input vector DNA released from the
shuttle plasmids by BamHI digestion. Lanes: 1, input vector DNA;
pSLB-luc digested with BamHI; 2, uncut SV/luc DNA; 3, SV/luc DNA
linearized with EcoRI; M, HindIII-digested  DNA. (B) The gel in (A) was
analyzed by Southern blotting with a pSLB-luc probe.
FIG. 2. Vector propagation in COT cell-lines. (A) IU of SV/luc vectors
stocks prepared in COS-1, COT2, COT4, and COT18 cell lines. (B)
luc-transducing activity of the vector stocks shown in (A). (C) After the
second passage, aliquots of vector stock prepared in COT2 cells were
further passaged, in parallel, in both COT2 and COS-1 cells. In a
parallel experiment SV/luc vectors were passaged continuously in
COS-1 cells.
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Replication-competent recombinants were assayed for
PFU by the standard plaque assay on CV-1PD cells. The
results of two independent experiments (Table 1) show
that replication-competent virus was not detected in four
different stocks prepared on COT cell lines. One of two
stocks prepared on COS-1 cells contained 1 PFU per
104 IU. In a third experiment, five stocks were propagated
separately on COT18 cells. No PFU were detected in any
of the stocks after five passages.
Discussion. Contamination by replication-competent
virus plagues viral vector stocks, including retroviral (13),
adenoviral (14), and adeno-associated viral (15) vectors.
The inherent instability of some viral vectors hinders the
ability to precisely predict the nature of contaminants in
vector stocks, thus raising serious safety concerns.
A number of investigators have reported the presence
of replication-competent recombinants in SV40 stocks
propagated on COS-1 and COS-7 cells (7–10). Here we
found a high proportion of plaque-forming SV40 (1 PFU
per 104 IU) in a vector propagated on COS-1 cells. The
COT cell lines were constructed in order to eliminate
homologous recombination by minimizing the regions of
identity between the packaging construct and vector
sequences. This strategy indeed appears to have elimi-
nated the emergence of replication-competent SV40.
However, although homologous recombination was pre-
vented, the vector DNA exhibited instability during prop-
agation in two of the three cell lines.
It has been shown (16) that successive undiluted pas-
saging of SV40 results in the production of defective
particles containing heterogeneous DNA that is shorter
than the DNA of plaque-purified SV40. Infection at a high
multiplicity allows the defective viral DNA molecules to
replicate, since T-antigen is supplied in trans by nonde-
fective virus infecting the same cell. Shorter DNA mole-
cules may have a selective advantage if they replicate
more rapidly or if they are more efficiently encapsidated
than full-length molecules. Our study shows that a sim-
ilar situation is present in SV40 packaging cell lines, as
the transgene that replaces T-antigen is not required for
completion of the viral life cycle and alterations in the
vector DNA that have a selective advantage in propaga-
tion are amplified.
The importance and problems of quantifying viral vec-
tor stocks have been recently discussed (17). Defective
vectors, whether replication competent or not, have been
reported in a number of viral vectors. This study high-
lights the problematic nature of various titration assays.
Titration based on the ability of vector particles to enter
cells, on vector replication, or on expression of viral
proteins may grossly overestimate the actual transduc-
ing capability of vector preparations.
The cell line constructed and characterized in the
present study offers a means for the preparation of safe
SV40 viral vector stocks at a high titer. Recent experiments
demonstrated that SV/luc stocks prepared on COT18 effi-
ciently transduced human hepatic cell lines such as HuH7
in vitro and liver hepatocytes in vivo following systemic
administration to BALB/C mice; published online (our un-
published results). The cloning capacity of these vectors,
2.2–2.4 kb, is sufficient for a number of therapeutic genes.
A promising alternative strategy is the production of vector
stocks in vitro using recombinant proteins (18). The plasmid
DNA to be packaged is prepared in appropriate Esche-
richia coli strains, minimizing the risk of accumulating mu-
tations or recombinants. That system combines the safety
of nonviral vectors with the efficient gene delivery of SV40,
affording the preparation of safe, effective vectors appropri-
ate for human use. Furthermore, it allows packaging of
significantly larger plasmids, as large as 17 kb (Kimchi-
Sarfaty et al., submitted for publication). Procedures for
large-scale, high-titer production of vectors prepared in
vitro are currently under development. It is anticipated that
the two alternative types of SV40 vectors will complement
one another in gene therapy applications.
Materials and Methods. Plasmid construction. Plasmid
pUMTB (Fig. 1A) was constructed in a pUC18 backbone
by combining the mouse metallothionein promoter (a
650-bp KpnI–XbaI fragment from plasmid pMT-tss (19),
the bovine growth hormone polyadenylation signal (a
260-bp XbaI to SphI fragment from pcDNA3 (Invitrogen))
and the SV40 T-antigen coding sequences (nucleotides
5179 to 2687, generated by PCR from SV40 DNA (GIBCO,
BRL)). The PCR primers 5-TAGGCTTCTAGAAAAAGCTT-
TGCAAAG-3 and 5-ACAATTGGGCCCATTTTATGTTTCA-
GGT-3 contained XbaI and ApaI restriction sites, respec-
tively (underlined). pUMTB carries a short (83 bp) overlap
with the SV40 vectors, coordinates 2687–2770 (Fig. 1B).
Plasmid pSLB is a T-antigen-deleted SV40 genome,
cloned as a BamHI fragment into pBR322. The T-antigen
coding region between the BclI site (SV40 nt 2770) and a
HindIII site (nt 5171) was replaced by an oligonucleotide
carrying HindIII–XbaI–PstI–BglII–SacI cloning sites. Plas-
mid pSLB-luc (Fig. 1C) was constructed by inserting the
luciferase gene, a HindIII–XbaI fragment from pGL3-ba-
sic (Promega), into the HindIII–XbaI sites of pSLB.
TABLE 1
IU Titer and PFU Titer of 5th-Passage SV/luc Stocks Prepared on
Various Cell-Lines
Cell-line IU Titer (/ml) PFU (/ml)a
Experiment #1 COS-1 1.5 107 0
COT2 1  107 0
Experiment #2 COS-1 5  107 6.3  103
COT2 4.4 107 0
COT4 3.8 107 0
COT18 7  107 0
a The sensitivity of detection was 3 PFU/ml.
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Construction of Cell Lines. Plasmids pUMTB and pLN
(20) were cotransfected into CV-1 and Vero cells by the
calcium–phosphate precipitation method. pLN carries a
neoR expression cassette and no SV40 sequences. Be-
fore transfection, fragments carrying the expression cas-
settes were excised from both plasmids and purified
following agarose gel electrophoresis. Plasmid pUMTB
was digested with SphI and KpnI and pLN with SacII and
NdeI. Forty-eight hours posttransfection the cells were
divided into selective medium containing 0.25 or 0.4
mg/ml G418 (Sigma). Antibiotic-resistant colonies were
isolated after 3 weeks at both G418 concentrations.
Vector Preparation. The bacterial sequences were ex-
cised off pSLB-luc by digestion with BamHI and religated
at a low DNA concentration (3 g/ml) as previously
described (1, 2). The ligated vector DNA was transfected
into logarithmically growing cultures with the Superfect
reagent (Qiagen). After transfection, COT cells were in-
cubated for 5 days in medium containing 0.1 mM ZnCl2
and 1 M CdSO4 for the induction of T-antigen expres-
sion. For COS-1 cells, the medium did not contain heavy
metals. Five days posttransfection the vector was har-
vested by three freeze–thaw cycles, followed by sonica-
tion. Cellular debris was removed by centrifugation at
3200 rpm (2135 g) for 30 min at 4°C. Vector preparations
were propagated by repeated cycles of infection and
harvesting. Infections were performed by incubating
cells with vector stocks (1.2 ml per 75-cm2 flask) for 2 h
at 37°C, with gentle rocking every 20 min, followed by
the addition of fresh medium. Harvest was performed 5
days later, as described above. Vector stocks were
stored at 20°C.
Titration and Luciferase Activity Measurement. Vector
stocks were assayed as infectious units by the in situ
hybridization method on CMT4 monolayers as previously
described (12). Luciferase activity was quantified by in-
fecting COS-1 cells with SV/luc vector preparations in a
24-well plate. All infections were performed in triplicate.
Forty-eight hours postinfection luciferase activity was
analyzed with the Steady-glo kit (Promega) and a SPEC-
TRAFluor Plus microplate luminometer (TECAN).
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